HK1206297A1 - Pharmaceutical compositions for combination therapy - Google Patents

Pharmaceutical compositions for combination therapy

Info

Publication number
HK1206297A1
HK1206297A1 HK15106790.2A HK15106790A HK1206297A1 HK 1206297 A1 HK1206297 A1 HK 1206297A1 HK 15106790 A HK15106790 A HK 15106790A HK 1206297 A1 HK1206297 A1 HK 1206297A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
combination therapy
therapy
combination
pharmaceutical
Prior art date
Application number
HK15106790.2A
Other languages
English (en)
Chinese (zh)
Inventor
Nicholas Waters Ross
Susanna Waters Eva
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of HK1206297A1 publication Critical patent/HK1206297A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15106790.2A 2012-04-04 2015-07-16 Pharmaceutical compositions for combination therapy HK1206297A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261620203P 2012-04-04 2012-04-04
US201261625192P 2012-04-17 2012-04-17
US201361783730P 2013-03-14 2013-03-14
PCT/US2013/035124 WO2013152105A1 (en) 2012-04-04 2013-04-03 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
HK1206297A1 true HK1206297A1 (en) 2016-01-08

Family

ID=49292803

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106790.2A HK1206297A1 (en) 2012-04-04 2015-07-16 Pharmaceutical compositions for combination therapy

Country Status (16)

Country Link
US (3) US20130267552A1 (ja)
EP (1) EP2844346B1 (ja)
JP (1) JP6177875B2 (ja)
KR (1) KR20150013476A (ja)
CN (1) CN104470585A (ja)
AU (1) AU2013243461A1 (ja)
BR (1) BR112014024672A8 (ja)
CA (1) CA2869145A1 (ja)
EA (1) EA027748B1 (ja)
ES (1) ES2776678T3 (ja)
HK (1) HK1206297A1 (ja)
IL (1) IL234831B (ja)
MX (1) MX2014011971A (ja)
NZ (1) NZ630560A (ja)
WO (1) WO2013152105A1 (ja)
ZA (1) ZA201407726B (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
PT2146961E (pt) * 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
KR20140008297A (ko) 2010-09-03 2014-01-21 아이백스 인터내셔널 게엠베하 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
AU2014281414A1 (en) 2013-06-21 2016-01-21 Teva Pharmaceuticals International Gmbh Use of high dose pridopidine for treating Huntington's disease
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
CN113975243A (zh) * 2014-04-25 2022-01-28 中外制药株式会社 以高用量含有四环性化合物的制剂
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
CN109923102B (zh) 2016-08-24 2022-11-15 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途
WO2018053280A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating rett syndrome
DK3570940T3 (da) 2017-01-20 2024-02-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse i behandling af fragilt x-syndrom
US11253594B2 (en) 2017-07-07 2022-02-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Drug combinations for protecting against neuronal cell death
PL3664787T3 (pl) 2017-07-20 2022-10-24 Neurolixis Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT
EP3668509B1 (en) 2017-08-14 2022-11-16 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
EA202090542A1 (ru) 2017-08-30 2020-06-08 Приления Ньюротерапьютикс Лтд. Высококонцентрированные лекарственные формы придопидина
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
WO2019050775A1 (en) * 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT
JP2021510971A (ja) * 2018-01-17 2021-04-30 ヒルシュマン カー コミュニケーション ゲゼルシャフト ミット ベシュレンクテル ハフツングＨｉｒｓｃｈｍａｎｎ Ｃａｒ Ｃｏｍｍｕｎｉｃａｔｉｏｎ ＧｍｂＨ 受信機システムから遠隔にあるｌｔｅモジュール
BR112020021700A2 (pt) * 2018-04-25 2021-01-26 Shinkei Therapeutics Llc dispositivo de distribuição transdérmica de tetrabenazina

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (ja) 1964-04-14
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ZA7546B (en) 1974-01-21 1976-08-25 Parke Davis & Co New antibacterial amide compounds and methods for their production
US4048314A (en) 1974-12-17 1977-09-13 Delmar Chemicals Limited Morpholino containing 4-arylpiperidine derivatives
US4202898A (en) 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
US4267328A (en) 1978-08-01 1981-05-12 Synthelabo 1-Phenylpiperazines
US4333942A (en) 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
US4485109A (en) 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
US4504660A (en) 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
DE3306964A1 (de) 1983-02-28 1984-09-06 Boehringer Ingelheim KG, 6507 Ingelheim Neues n-arylpiperazin und verfahren zu seiner herstellung
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
DE69231854T2 (de) 1991-04-17 2001-10-04 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
DE69232003T2 (de) 1991-09-18 2002-04-25 Glaxo Group Ltd Benzanilidderivate als 5-HT1D-Antagonisten
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
IL112099A (en) 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
IL114027A (en) 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
WO1997003986A1 (fr) 1995-07-19 1997-02-06 Yoshitomi Pharmaceutical Industries, Ltd. Composes fusionnes de triazole
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ES2225979T3 (es) 1996-07-22 2005-03-16 Daiichi Suntory Pharma Co., Ltd. Derivados de arilpiperidinol y de arilpiperidina y farmacos que los contienen.
US5892041A (en) 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
US6159979A (en) 1997-04-18 2000-12-12 Smithkline Beecham P.L.C. Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
BR9714787A (pt) 1997-06-10 2000-07-18 Synthon Bv Compostos de 4- fenilpiperidina e processo para sua preparação
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
JP4569980B2 (ja) * 1997-08-07 2010-10-27 株式会社フジモト・コーポレーション 新規なエチルアミン誘導体
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
WO2000030649A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
NZ515543A (en) 1999-06-22 2003-11-28 Neurosearch As Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
US6455543B1 (en) 1999-07-30 2002-09-24 University Of Kentucky Research Foundation Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
WO2002005819A1 (en) 2000-07-15 2002-01-24 Smithkline Beecham Corporation Compounds and methods
WO2002059117A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA06013941A (es) 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
DK1773772T3 (da) 2004-06-08 2010-09-13 Nsab Af Neurosearch Sweden Ab Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission
US7884104B2 (en) 2004-10-01 2011-02-08 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
DK1802573T3 (en) 2004-10-13 2016-12-19 Teva Pharmaceuticals Int Gmbh METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE.
NZ555095A (en) 2004-10-13 2010-07-30 Nsab Af Neurosearch Sweden Ab Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
RU2394821C2 (ru) 2005-08-22 2010-07-20 Солвей Фармасьютикал Б.В. N-оксиды как пролекарства производных пиперазина и пиперидина
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
JP2009518337A (ja) 2005-12-07 2009-05-07 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ 皮質カテコールアミン作動性神経伝達のモジュレーターとしての二置換フェニルピペリジン
WO2007128694A1 (en) 2006-05-02 2007-11-15 Solvay Pharmaceuticals B.V. N-oxides of pyridylmethylpiperazine and -piperidine derivatives
JP2009536187A (ja) 2006-05-05 2009-10-08 アステックス・セラピューティクス・リミテッド 癌の処置のための４−（２，６−ジクロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸（１−メタンスルホニル−ピペリジン−４−イル）−アミド
EP1961742A1 (en) 2007-02-22 2008-08-27 Novartis AG compounds of formula (I) as serine protease inhibitors
WO2008112278A2 (en) * 2007-03-12 2008-09-18 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
PT2146961E (pt) 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CN101765428A (zh) * 2007-06-18 2010-06-30 A·卡尔森研究股份有限公司 多巴胺稳定剂的用途
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
CN102369202A (zh) 2008-11-13 2012-03-07 链接医药公司 氮杂喹啉酮衍生物及其应用
CN102548986A (zh) * 2009-06-05 2012-07-04 链接医药公司 氨基吡咯烷酮衍生物及其用途
US20120122848A1 (en) 2009-07-29 2012-05-17 Green Cross Corporation (+)-3-hydroxymorphinan derivatives as neuroprotectants
EP2464340A2 (en) * 2009-08-12 2012-06-20 Valeant International (Barbados) SRL Pharmaceutical compositions with tetrabenazine
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130203886A1 (en) 2010-03-05 2013-08-08 Nileshkumar Prakash Kukalyekar Process for the production of an uhmwpe article
EP2576552A4 (en) * 2010-06-01 2013-11-13 Aupex Pharmaceutical Inc BENZOQUINOLONE INHIBITORS OF VMAT2
WO2012002863A1 (en) 2010-07-02 2012-01-05 Aktiebolaget Skf Mechanical component and method for surface hardening
KR20140008297A (ko) 2010-09-03 2014-01-21 아이백스 인터내셔널 게엠베하 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽

Also Published As

Publication number Publication date
ZA201407726B (en) 2016-05-25
MX2014011971A (es) 2015-01-16
CN104470585A (zh) 2015-03-25
WO2013152105A1 (en) 2013-10-10
JP6177875B2 (ja) 2017-08-09
EA027748B1 (ru) 2017-08-31
CA2869145A1 (en) 2013-10-10
BR112014024672A8 (pt) 2018-04-03
EP2844346B1 (en) 2020-01-01
US11207308B2 (en) 2021-12-28
IL234831A0 (en) 2014-12-31
US20200000785A1 (en) 2020-01-02
EA201491819A1 (ru) 2015-04-30
BR112014024672A2 (ja) 2017-06-20
US20130267552A1 (en) 2013-10-10
US20170266170A1 (en) 2017-09-21
EP2844346A4 (en) 2015-11-18
EP2844346A1 (en) 2015-03-11
IL234831B (en) 2020-10-29
AU2013243461A1 (en) 2014-11-06
ES2776678T3 (es) 2020-07-31
JP2015515475A (ja) 2015-05-28
NZ630560A (en) 2016-11-25
KR20150013476A (ko) 2015-02-05

Similar Documents

Publication Publication Date Title
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
ZA201703992B (en) Inhalable pharmaceutical compositions
HK1213798A1 (zh) 治療性化合物和組合物
HK1209638A1 (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1209047A1 (en) Novel pharmaceutical composition
GB201420971D0 (en) Therapeutic composition
IL217807A0 (en) Therapeutic compositions
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
HK1209339A1 (en) Pharmaceutical formulations
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
PT2814473T (pt) Composições farmacêuticas para terapia de combinação
IL238075A0 (en) pharmaceutical preparations
ZA201400751B (en) Pharmaceutical composition
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions
GB201221130D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition
GB201211406D0 (en) Pharmaceutical formulations